Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Rating of “Buy” from Brokerages

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRMGet Rating) has received an average rating of “Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $50.20.

MIRM has been the subject of a number of analyst reports. SVB Leerink increased their price target on Mirum Pharmaceuticals from $46.00 to $49.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 26th. Raymond James increased their price target on Mirum Pharmaceuticals from $70.00 to $74.00 and gave the stock a “strong-buy” rating in a research note on Friday, March 11th.

Several institutional investors have recently modified their holdings of MIRM. BVF Inc. IL purchased a new position in shares of Mirum Pharmaceuticals during the third quarter valued at about $8,684,000. AIGH Capital Management LLC purchased a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at about $5,389,000. BioImpact Capital LLC purchased a new position in shares of Mirum Pharmaceuticals during the third quarter valued at about $6,146,000. Silvercrest Asset Management Group LLC purchased a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at about $4,566,000. Finally, AXA S.A. grew its position in shares of Mirum Pharmaceuticals by 28.8% during the third quarter. AXA S.A. now owns 852,172 shares of the company’s stock valued at $16,975,000 after purchasing an additional 190,580 shares in the last quarter. Hedge funds and other institutional investors own 87.68% of the company’s stock.

Shares of Mirum Pharmaceuticals stock opened at $21.70 on Thursday. Mirum Pharmaceuticals has a one year low of $12.82 and a one year high of $28.65. The stock’s fifty day moving average is $23.95 and its 200 day moving average is $19.56. The stock has a market cap of $690.82 million, a P/E ratio of -9.60 and a beta of 1.23.

Mirum Pharmaceuticals (NASDAQ:MIRMGet Rating) last announced its earnings results on Thursday, May 5th. The company reported ($1.17) EPS for the quarter, topping analysts’ consensus estimates of ($1.39) by $0.22. Mirum Pharmaceuticals had a negative return on equity of 171.16% and a negative net margin of 218.74%. During the same period in the previous year, the company posted ($1.68) EPS. As a group, equities research analysts anticipate that Mirum Pharmaceuticals will post -4.98 EPS for the current fiscal year.

About Mirum Pharmaceuticals (Get Rating)

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.

See Also

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.